For cancer center and ins co consideration v4 2

THE CHALLENGE OF ACHIEVING WORLD CLASS CANCER CARE AND GROWING LONG DISTANCE CANCER ADVISORY AND GENOMIC TESTING IN EMERGING MARKETS

GLOBAL CARE, EVERYWHERE”

EXECUTIVE SUMMARY

This presentation explores these needs and details the potential opportunity to be developed and a way to serve this need by developing service networks linking US Genomic Labs and Cancer Centers with international patients in Emerging Markets; TestAnalytika as a Value Added Integrator enables this relationship

Confidential and for discussion only 2

Talks:3 dozen top oncologists

Survey:50+ oncologists

Problems affecting patients:1) Ordering and Follow up2) Certified translations3) Payments & Logistics4) US advisory and know

how5) Insurance Co. buy inSolutions- access to: - Advanced genomic tests & results - Referential Treatment Protocols &

Diagnostic Decision Support- Cancer Management techniques and US

Cancer Center Long Distance Advisory- Insurance Coverage & Prepay payment

aids

Not available in Emerging Markets- Support in locating, ordering and

interpreting US based molecular diagnostic Genomic Tests

- Easy access to US based Cancer Center Support

05/01/2023Confidential and for discussion only 3

THE CHALLENGE OF MAKING A HIGHER LEVEL OF CANCER CARE ACCESSIBLE FOR EXPATS

Top level cancer diagnosis &

Genomic Testing

The Gap

• Affordability / Lack of insurance Coverage

• Lack of access and follow up• Language barriers• Logistics issues• Interpretation of results

Expat Families



Expat Families

• Insurance Coverage• IT Platform for tracking and

follow up + EMR transmission

• Translation of results• Coordination with Fedex• Links with US Cancer Centers

for Remote Advisory and Diagnostic Decision Support

Our Proposal

Top level cancer diagnosis &

Genomic Testing

Confidential and for discussion only


The Gap is Closed

IMPROVING ACCESS TO MEDICINES AND ONGOING

THERAPEUTIC SUPPORT WOULD COME IN PHASE II


The Challenge

The Target Market

Our Proposal

Go to Market

Business Plan

Team


The ChallengeWhat the Problem is in Emerging Markets for Expats and Others

05/01/2023 8

CANCER INCIDENCE IN LATIN AMERICA AND CARIBBEAN (LATAM-C) IS AROUND ONE MILLION CASES PER YEAR, CONCENTRATED IN FIVE MAJOR CANCER TYPES AND WITH STRONG LONGTERM GROWTH

The Challenge


CANCER INCIDENCE IN LATIN AMERICA AND CARIBBEAN (LATAM-C) IS AROUND 70% OF THE USA’S, YET FIVE YEAR CANCER SURVIVAL RATES IN LATAM-C ARE ONLY 50% OF THE USA’S

While Latin Americans contract cancer at lower rates than residents of the United States, they are nearly twice as likely to die from it, the (Lancet) study said … "If corrective action is not taken this problem will become magnitudes of order bigger than it is today, it will create massive human suffering and it will threaten the economies of the region," Paul Goss, a professor at Harvard Medical School who led the study, said at an event in Sao Paulo on Friday. 04/26/2013http://www.huffingtonpost.com/2013/04/26/latin-america-cancer-epidemic_n_3165463.html

http://globocan.iarc.fr/ 2012

US vs LatAm-C Incidence and Mortality

50%

70%

The Challenge

Equal

http://globocan.iarc.fr/

http://globocan.iarc.fr/


TWO SOLUTIONS HAVE STOOD OUT FOR US TO ADDRESS:1) ACCESSING US BASED CANCER CARE AND 2) ACCESSING US BASED CANCER LABORATORIES

US BASED CANCER CARE

Alliances between US medical institutions via partnership or sister institution agreements with leading LatAm Hospitals and Medical Centers

US BASED LABORATORIES US Labs have

established alliances with LatAm medical and pharmaceutical reps to represent them and develop business in LatAm

The Challenge

IMPROVING ACCESS TO MEDICINES

AND ONGOING

THERAPEUTIC SUPPORT

WOULD COME IN PHASE II


US HOSPITALS HAVE LONG BEEN ATTRACTIVE FOR THE INTERNATIONAL MARKET SEEKING TOP LEVEL CARE – BUT LIMITED TO HIGH INCOME INDIVIDUALS

http://www.forbes.com/2008/05/25/health-hospitals-care-forbeslife-cx_avd_outsourcing08_0529healthoutsourcing.html

The Challenge

McKinsey & Co.:Medical Travelers to USA60K to 80K per year

Medical Travelers:32% want better care15% quicker access9% lower prices4% low cost procedures

Latin America has been mentioned as representing a proportionally higher number of patients for US medical centers

In Depth: U.S. Hospitals Worth The Trip, but affordable only by the top 1-3%



05/01/2023 12

GENOMIC CANCER TUMOR PROFILING AND OTHER US BASED GENOMIC LAB SUPPORT HAVE NOT GAINED MUCH TRACTION IN LATIN AMERICA VS. INHERENT POTENTIAL

FIRST WORLD GROWTH

The Challenge

LATIN AMERICAN CHALLENGES “ We frequently encounter delays of up to

three our four months in receiving our biopsy results because we have no direct contact with the laboratory doing the genetic testing.”

- Argentine physician “ We do not send many samples to the US

because for us the process is difficult and complicated. Many of my colleagues do not speak English.”

- Peruvian physician “the process is slow, expensive and

complicated… it would be interesting to have an easier method.. .Through our agreement with Johns Hopkins, we have access to their treatment protocols and opinions, but it is a very slow and complicated process.”

- Chilean physician

BOTH SOLUTIONS HAVE UNDERPERFORMED vs THEIR POTENTIAL (1)

Conflict between feeder model of bringing patients to the US and extension model of leveraging intellectual capital overseas

Lack of a clear business strategy, low priority and subordination to US based growth or international exposure in more important regions

Lack of clarity and alignment in relationship with foreign medical institutions Informal definition of support relationship – frequently only dependent upon periodic

teleconference case discussions No clear business model as to how to generate revenues and create mutual value from the

relationship – ‘sister institution’ not linked to goals - ‘Ad hoc’ model of support only when called upon

Low level of accountability for growth or development of the relationship and no P&L responsibility

Not tied in to other global initiatives done by institutions such as development of Fellows, Post Doctorate internships and use of international Alumni as a point of contact and growth

US institution may invest in the relationship and not develop channels to harvest many potential benefits

Separation between the Academic and the Clinical sides are failing to exploit synergies and economies of scale, relationships and branding among the different areas – ‘feudal castles’

05/01/2023Confidential and for discussion only

EXPANSION OF US BASED CANCER CARE

The Challenge

05/01/2023Confidential and for discussion only

BOTH SOLUTIONS HAVE UNDERPERFORMED vs THEIR POTENTIAL (2)

1. Logistics issues and enrollment problems due to a limited non-US focus of these labs and lack of flexibility for non-US patients in term of sign up (web pages focused on US market only, US dollar payment only, English language results only).

2. Follow up on test progress and lack of “Concierge Service” - difficulty in following up progress of clinical analyses through the laboratory and Annotation processes.

3. Difficulty in interpreting lab results due to language difficulties and limited MD experience base in evaluating impact of genomic tests on therapies, lack of Diagnostic Decision Support integrating Clinical History with test results and Annotations

4. High out of pocket costs – USD 7,000 – 10,000 per case w/o insurance coverage in practically all cases and problems with access to US Dollars in certain countries

5. Translation of results into local language; certification of EMR translations into English

6. Overall, a fragmented value chain and no one to integrate multiple players

US BASED GENOMIC LABORATORIES

The Challenge

LINKING US GENOMIC TESTING PLUS LONG DISTANCE CANCER ADVISORY SERVICES COULD BE A POWERFUL ONE-TWO PUNCH

LONG DISTANCE CANCER ADVISORY SERVICES

US GENOMIC TESTING


15

05/01/2023

• US based Cancer Institutions are sine qua

non the leaders in Cancer Care

• Expanding this intellectual capital

overseas is a challenge, but one that, if

resolved, would support both their Hippocratic

and institutional development goals

• Genomic Testing is a growing frontier and one that US Cancer

Centers are developing aggressively

• US Genomic Testing labs are focused on the US Market, but their capabilities and expertise could jumpstart an improvement in global cancer care

• Limitations in outreach, operations, fulfillment and payment (insurance) mechanisms limit their ability to grow overseas

• The support of US Cancer Centers would make their services more accessible and useable

The Challenge

Expandable to Neuro and Cardio from Onco


WE BELIEVE THE CHALLENGE IS TO GET THE MOST OUT OF ADVANCED GENOMIC TESTING BY BRACKETING WITH A SERIES OF SERVICES THAT MAKE IT MORE ACCESSIBLE AND USEFUL TO INTERNATIONAL MDS AND PATIENTS

Financial, Marketing

and Logistics Support

Genomic Test

The Challenge


The Target MarketWho the Consumers are in Lat Am


LATIN AMERICA PRESENTS MANY CONDITIONS THAT MAKE IT APPROPRIATE TO LAUNCH A PROGRAM LIKE TAK’S

MD’s have expressed a demand for the Service due to lower level of familiarity with Genomic Testing

High economic growth centered around an emerging middle class Tight links with the US and brand recognition of its medical centers Private medical care is available for Medium and Higher income

individuals Age pyramid trending towards the peak Cancer years – 40+ Growing private insurance sector Fairly open in foreign exchange conversion, although with roadblocks

and hurdles

The Target Market


LATIN AMERICA PRESENTS A CONSOLIDATING AND RAPIDLY AGEING MIDDLE CLASS WHICH IS OUR TARGET MARKET

The Target Market


OUR TARGET MARKETS IN LATAM START WITH PREPAY AND THOSE COVERED BY INSURANCE AND WILL EVENTUALLY GROW TO THE PUBLIC SECTOR

Current Sector- Prepay/Selfpay

Clients

Target Sector- those with Insurance Coverage

Final Sector – Public Sector Clients

Around 3-5% or 18-30MM people

Around 15-18% or 100MM people

Around 80% or 500MM people

Have the financial wherewithal, but lack the value chain support needed to utilize these services

Could access these services with insurance coverage and value chain support

Could access these services with Public Sector help and value chain support

The Target Market


LATIN AMERICA HAS A CLASS OF HIGHER NET WORTH INDIVIDUALS THAT WOULD PAY TO USE THESE GENOMIC TESTS AND US CANCER ADVISORY SERVICES; THEY COMPRISE 3-5% OF THE TOTAL OR 18-30MM OF THE 600 MM POPULATION

Analisis Lambda International Consultants, Data base from respective sources in each country

Using 0.15% cancer incidence rate, this represents 30-50,000 cancer cases per yearPrePay individuals

have been hampered by the logistics, fulfillment and

integration of multiple players required to

access services, irrespective of

payment capabilities

The Target Market


LATIN AMERICAN PRIVATE HEALTH INSURANCE COVERS 100MM PEOPLE – 4X TO 6X MORE

Latin American Private Health Insurance is a USD 38BN Industry covering 100 MM people

Reaching 1% of insured would be 1MM people

Country% covered

Private insurance

Population MM

Number Covered MM 1% of Insured

Argentina 10% 40 4.00 40,000 Brasil 30% 190 57.00 570,000 Chile 16% 17 2.70 27,000

Colombia 35% 45 15.53 155,250 Mexico (1) 8% 110 8.80 88,000

Peru 4% 30 1.05 10,500 Venezuela 9% 30 2.78 27,778

Total 20% 462 91.85 918,528 Other areas 10% 150 15.00 150,000

Total Latam-C 17% 612 106.85 1,068,528 Source: Mapfre Insurance, Latin American Health Systems, 2009;(1) http://www.facmed.unam.mx/sms/temas/2010/03_mar_2k10.pdf Analysis by Lambda International Consultants

Insurance companies have not had an external partner to support them

in integrating the logistics, fulfillment and integration of multiple

players required to access services,

irrespective of payment capabilities, in addition

to the outreach and other support functions

required for international programs

The Target Market


WE ESTIMATE THAT 6MM IS THE ADDRESSABLE AND CAPTURABLE MARKET FOR AN INSURANCE PROGRAM OFFERING GENOMIC TESTING AND US CANCER SUPPORT= 1% OF THE POPULATION

High Net Worth Insured Middle Class Insured01020304050607080

30

70

3 3

27

67

Capturable Market

Total MM Genomic Insurance Buyers Non Buyers


ENGAGING THE PUBLIC SECTOR WOULD ULTIMATELY ACCESS MOST OF LATIN AMERICA’S POPULATION IN THIS INITIATIVE

Percentage of the Population in LatAm

Self Pay Insurance Public Sector

• Public Sector users have neither insurance nor PrePay-SelfPay capabilities

• Nevertheless, they are a huge number and incorporating them into a program would reduce cost and absorb fixed costs enormously

The Public Sector is a more long term goal, but

once the value and feasibility of these

Programs are demonstrated in Private Sector Initiatives, it is

certain that a percentage of the Public

Sector will move to adopt similar offerings

The Target Market


Our ProposalWhat we Propose to the Consumers in Lat Am


OUR PROPOSAL IS TO DEVELOP AN INSURANCE BASED SYSTEM OF COVERAGE WHICH WILL ALSO SUPPORT SELFPAY/PREPAY AND ULTIMATELY LEAD TO PUBLIC SECTOR ADOPTION

Prepay TAK SUPPORT PLATFORM MEDICAL , FINANCIAL INSTITUTIONS AND MDs

Insurance TAK SUPPORT PLATFORM BROKERS, INSURANCE COMPANIES, AFFILIATED MDs

Public TAK SUPPORT PLATFORM PUBLIC SECTOR INSTITUTIONS

Our Proposal

PAYMENT CHANNEL EXECUTION/FULFILLMENT OUTREACH

FIRST PHASE

LATER PHASE


OUR SUPPORT PLATFORM WOULD USE INFORMATION TECHNOLOGY TO INTEGRATE THE DIFFERENT PLAYERS STARTING AT THE INSURANCE COMPANIES PLUS PROVIDE A SECURE DATA EXCHANGE, TRACKING AND PAYMENT PLATFORM

05/01/2023

Our Proposal

DATA EXCHANGED• Patient information• Payor information• Logistics information

INS CO.

PAYORS DATA EXCHANGED• Test information• DDS/Medical opinion information• Patient Progress information

TRANSLATIONSERVICES

PAYEES

WE PROPOSE TO OFFER AN INTEGRATED LEVEL OF SERVICE TO MD’S AND PATIENTS IN LATAM-C TO FACILITATE ACCESS TO US CANCER CENTER SUPPORT AND GENOMIC CANCER TESTING

Leading Cancer Center Long Distance Cancer Advisory Services and

Consultations1. PreTest Long Distance Cancer

Advisory Services for Patients in stages I-IV

1. Prior to the execution of Molecular Diagnostic tests

2. Could include genetic test for inherited risks

2. PostTest Long Distance Cancer Advisory Services for Patients in stage IV

1. Following the execution of Molecular Diagnostic tests

Molecular Diagnostic Laboratory advisory and support

1. Send biopsies and samples for laboratory work in US at Molecular Health or other labs

1. Molecular Health would be the supplier of choice for genomic analysis, but pursuant to local MD selection and approval

2. Support in logistics and processing3. Translation of laboratory results4. Secure platform for data transmission5. Oncological review of genomic test results,

1. TAK’s pool of top oncologists would supply a review of the test results providing Diagnostic Decision Support and orientation in terms of Cancer Management for the patient linking test results with patient EMR

6. The program is also investigating different value added financial options, apart from basic insurance coverage; these include:

1. Support in FOREX conversions if needed2. Financing options for those that want to self pay, not insure


Our Proposal

Later phases would

include testing for hereditary cancers in Stages I-III


BASIC SERVICE – GENOMIC TESTING, MOLECULAR DIAGNOSTIC LABORATORY ADVISORY AND SUPPORT – MOSTLY FOR STAGE IV PATIENTS AS REQUESTED BY THE LOCAL MD

US Lab would perform Genomic Testing at its leading edge facility – Molecular Health has been contacted and has a signed LOI to perform this service- others would depend on MD request

Support in logistics and processing ensuring timely delivery of results Translation of laboratory results and management of EMR transmissions via

HIPAA approved channels; hardcopy transmissions via Fedex or other carriers Diagnostic Decision Support, Referential Protocols and Cancer Management

support based on test results (provided by external oncologists) A Portal to assist Patient/MD/Pathologist would agglomerate relevant recent

research in order to assist the patient’s treatment and knowledge Email support for the physician would be maintained for 30 days from date of

delivery of test results Patients prior to Stage IV would not be covered in the Basic Service

Our Proposal

30

PREMIUM– COMPLETE LONG DISTANCE CANCER ADVISORY AT A US CANCER CENTER INCLUDING GENOMIC TEST, ADVISORY AND SUPPORT IF APPROPRIATE AND REQUESTED BY THE LOCAL MD – FOR PATIENTS FROM STAGE I-IV

Patients in Stages I-III would proceed to a Complete Long Distance Cancer Advisory Service focused on advising the local MD with transmission to the USA of all relevant EMR’s and other clinical information for the US MD to make an informed evaluation of the case and alternatives.

Genetic test for inherited predisposition in children of affected parent could be included Were this case to evolve into Stage IV then the local MD would have the option to order a

Genomic Test from one of the labs affiliated with the program- Molecular Health as the preferred provider. Patients that enter already at Stage IV could start at the Molecular Diagnostic testing stage or the Long Distance Cancer Advisory Service

US Lab would perform Genomic Testing at its leading edge facility – Molecular Health has been contacted and has a signed LOI to perform this service as our preferred provider

Support in logistics and processing ensuring timely delivery of results Translation of laboratory results Diagnostic Decision Support, Referential Protocols and Cancer Management support based on test results

provided by external oncologists A Portal to assist Patient/MD/Pathologist would agglomerate relevant recent research in order to assist the

patient’s treatment and knowledge Email support for the physician would be maintained for 30 days from date of delivery of test results

The Complete Long Distance Cancer Advisory could occur before or after the Genomic Tests were in, with timing depending on the results; In some cases it could precede and evaluate the usefulness of genomic tests depending on local MD input.


Our Proposal


OUR SUMMARY OF THE INSURANCE COVERAGE PROPOSED

BASIC SERVICEStage IV

onlyGenomic Test

Diagnostic Decision Support

PREMIUM SERVICEStage I-IV

at discovery

US CANCER CENTER ADVISORY

SERVICE

Our Proposal

Diagnostic Decision Support

GENOMIC TEST

TIME LAPSE UNTIL STAGE IV *

* IF NO STAGE IV, GENOMIC TEST AND DDS REPLACED BY TWO FOLLOW ON US CANCER CENTER ADVISORY SERVICES; IN Stage IV TEST MAY PRECEDE ADVISORY SERVICE

US CANCER CENTER ADVISORY

SERVICE

OPTIONAL CASH PURCHASE

MH as preferred provider

MH as preferred provider of Genomic Test; Diagnostic Decision Support performed by one of the leading US Cancer Centers

STRUCTURED INSURANCE PRODUCT OFFERINGS – ESTIMATED PRICE TO CLIENT IS AFFORDABLE TO THE MIDDLE CLASSLatin America Standard Pricing(Family=4 people)

Insurance Coverage USD(Nominal Value)

Coverage Starts at

Genomic Test

Diagnostic Decision Support via US Oncologist

No of distance consultationsWith US Cancer Center

Estimated annual Premium(actual figures may vary)

Basic Individual

USD 12,500

Metastasis (Stage IV)

None USD 35

Basic Family

USD 12,500

Metastasis (Stage IV)

None USD 130

Premium Individual

USD 17,500

Discovery (Stage I,II or III)

One Pre Test

USD 70

Premium Individual

USD 17,500

Discovery(Stage IV)

One Post Test

USD 70

Premium Family

USD 17,500

Discovery (Stage I,II or III)

One Pre Test

USD 200-225

Premium Family

USD 17,500

Discovery (Stage IV)

One Post Test

USD 200-225

Our Proposal

Nominal Value is for Consumer evaluation only; Basic and Premium have costs defined on a per Company basis


THE USD 200 COST PER FAMILY IS LOW COMPARED TO TOP LEVEL LOCAL AND GLOBAL/INTERNATIONAL MEDICAL INSURANCE COSTS

AVERAGES BASED ON INTERNATIONAL AND LOCAL COVERAGE FOR FAMILY OF 4


OUR PROGRAM TO COMPLEMENT INSURANCE WAS WELL RECEIVED IN LATAM-LAUNCH IS IMMINENT TestAnalytika has launched its first policy into Latin America and the

Middle East via Redbridge It expects to launch the second policy via a grey market broker in Ecuador

in 35 days; TestAnalytika has presented this program to insurance companies in

LatAm with strong response TestAnalytika is also working with local financial institutions to

establish a payment plan for those who do not have insurance coverage Part of this financing may be covered by credits in life insurance policies

Employee Benefit Plans have also emerged as a recent target of interest

Our Proposal

WE HAVE CONTACTED MANY OF THE PREMIER US MEDICAL CENTERS FOR SUPPORT

Leading Cancer Center Long Distance Cancer Advisory Services and

Consultations1. Memorial Sloan Kettering (Oral

agreement in place with email confirmation)

2. UM Sylvester Cancer Center (Oral agreement- contract underway)

3. UC San Diego (In talks scheduled for Sept 15)

4. Penn Medicine (Oral agreement)5. Memorial Health System, FL (In

talks)6. MD Anderson (Oral agreement)7. UC San Francisco (Visit

scheduled for Sept)

Molecular Diagnostic Laboratory advisory and support

1.Signed LOI with Molecular Health; Foundation Medicine, others under review

2.Access if needed Genomic Labs at Memorial Sloan Kettering, MD Anderson, UPenn, UMiami


Our Proposal


Go To MarketHow to reach the Consumer


INSURANCE COMPANIES IN LATAM ARE CLEARLY IDENTIFIED AND TARGETED

Go to Market

These companies could be targets for

taking on risk themselves or

fronting underwritten policy


OUR INSURANCE MARKET LOCAL PARTNERS ARE SOLID FIRMSCOUNTRY GROUP OBSERVATIONS

Mexico MASA/others pending

Third generation insurance executives invoicing over USD 50MM in premiums with top level access to all insurance companies

Brasil TBD In conversations with JLT, Marsh, other major groups to complete alignment

Colombia Vista Financial and Consulting

Boutique financial advisory firm that includes the ex COO of Liberty Mutual Europe; also ex CEO of LM Venezuela

Peru F4SI/others Regional foundation focused on Healthcare and Education initiatives; participating as a JV partner focused on Public sector

Ecuador PROANO Multiple allies among the top firmsVenezuela MaKler Strong local company with top flight

clientbase

Go to Market


OUR WORKING RELATIONSHIPS ARE AIMED AT MAXIMIZING SALES AND MINIMIZING INVESTMENTS TAK has proposed a joint profit sharing relationship with the local

partners, reducing our share of capital expense and increasing traction in the markets They share with us the insurance company commissions, in exchange for

supervision of the day to day relationship and the sales and marketing efforts

The S&M efforts would be paid for out of the 5% S&M fee The local partner would also get a commission on each test sale resulting

from the insurance company relationship Local Partner would be lead broker, supervising other brokers and leading

Sales and Marketing and Medical Education activities

Go to Market


A KEY SALES AND MARKETING WILL BE TO INCREASE LATAM MD’S AWARENESS AS TO GENOMIC TESTING AND THE ADVANTAGES OF US CLINICAL SUPPORT

Go to Market

25%

57%

18%

What percentage of patients would you perform genomic tests on?

n=160 US MD's

Over 90%

In between

Less than 10%

Even in the US there is an

enormous gap in awareness of Genomic

Testing


OUR MARKETING STRATEGY IS A MIX OF TRADITIONAL AND SOCIAL MEDIA USING 5% OF INSURANCE PREMIUMS COLLECTED

25%25%25%

20%

5%

TAK's Proposed Market-ing Budget

Trad. DetailingE-DetailingB2C Social MediaEvents & Hospi-talsTrad. Media

Go to Market

Trad.

Detailin

g

E-Deta

iling

B2C So

cial M

edia

Events

& Hospita

ls $-

$2,000 $4,000 $6,000

Cost per Medical Center Per Year


Business PlanWhat the business would look like


FOUR CHANNELS ARE AVAILABLE FOR US WITHIN INSURANCE AND RELATED FIELDS

Traditional Onshore

Insurance Channel

(via Straight Risk or

Fronting +Reinsurance)

Traditional Offshore Grey

Market Companies

Employee Benefit Plans via Insurance

based packages

Direct to Consumer via Online Access ( onshore or

offshore policy)

Business Plan


OUR BUSINESS PLAN FOR A LOCAL PARTNER LIKE YOU REVOLVES AROUND THESE AREAS

Business Plan

1. Sell within and to your existing client base1. Link up with a local onshore company that wants to develop or just front

the product2. If legally viable, sell an offshore product as “medical travel insurance” –

note that all payments to providers are made in the US, no conflict with local insurance regulators

2. Develop international executive benefits plan business through distribution partners and existing corporate clients

1. May be via a Captive Insurer for tax benefits2. May be via an offshore “Mutual Insurance Company” to reduce costs

3. Sell directly into new areas by use of internet and other channels


OUR CONSERVATIVE ESTIMATE FOR ARGENTINA IS AROUND 15-20,000 PEOPLE COVERED- REACHING 1% OF THE POPULATION WOULD BE 400,000 PEOPLE Covering 5,000 families at USD

225/family means over USD 1,100K premiums

Local Partner take of 20% is over USD 220K

Additionally, 5% commission on services provided upon cancer incidence should generate USD 20K more in fees

Business Plan

Year 1 Year 2 Year 302000400060008000

10000120001400016000

People Covered

People


TeamWho would run the program


LIN GIRALT Lin Giralt is Managing Director of Lambda International Consultants, LLC, Houston,

TX and Adjunct Professor, Jones Graduate School of Business at Rice University. Lin has over 30 years work experience of which 20 years are in consulting. He started his

consulting career with McKinsey & Company and Booz-Allen & Hamilton leading projects throughout all of Latin America and founded Lambda in 1997. His main focus is corporate strategy, processes, organization and market entry strategies. His focus is on startups, medium sized businesses and how to help them become more competitive in a globalized economy.

In the medical field, Lin designed all the business and commercial processes for a major plastic surgery clinic, reviewed the commercial strategy and logistics for a major pharmaceutical products manufacturer and helped a distributor of prosthetic products segment the market and develop a more effective go to market strategy.

Prior to consulting he served as Operations and Sales Manager for a family owned agribusiness and Construction Manager for a series of office and industrial projects in the US and overseas.

Lin Giralt is Chairperson of the Rice Graduate Alumni Committee and is also former Vice-president of Houston’s MBA Council. In addition to a Rice M. Architecture degree, he holds a B.A. from Duke University and an M.B.A. in Finance and Real Estate from The Wharton School. Married (32 years), two kids, four cats, one dog. He is a Golfer and Squash player, a student of history and military and business strategy

Team


ZEKE WIMERT Zeke Wimert has been a senior leader at Fortune-500, multinational and

start up technology companies, Zeke has extensive experience as a thought leader and builder of profitable, high profile operations in various industries and markets, both in the United States and Internationally.

He has held senior roles as CEO, COO and Senior Vice President-level assignments at global companies such as National Semiconductor, Motorola and Oracle, as well at successful start up organizations such as Unitools, AboveNet Communications and OptiConnect. His industry expertise spans semiconductors, enterprise software, telecom infrastructure products, high-availability internet networks, and carrier voice and data services.

Over the past seven years as a consultant, he has been actively involved in management and acquisitions of a wide range of companies in the US and internationally, including direct management roles in turnaround situations in exceptionally complex, fast-moving markets.

Zeke Wimert graduated from the United States Military Academy and received a degree in Applied Engineering, followed by a Masters degree in Economics, with honors, at the State University of New York at Stony Brook as well as graduate work in Operations Research and Systems Analysis at Georgia Tech.

Team

Our Team is building up, we hope this presentation clarifies doubts and your organization can join us


Team

EXECUTIVE TEAM

INSURANCE COMPANIES & BROKERS

US CANCER CENTERS

US GENOMIC LABS

Health & Medicine

For cancer center and ins co consideration v4 2